Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10605435 | 1.00 | LMNA (0.52) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL28275254 | 0.85 | CYP3A4 (0.49) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL1711563 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL29674753 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL430516 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL3055513 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL1417856 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL915218 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL2889714 | 0.82 | LMNA (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A | |
| SCHEMBL27514640 | 0.81 | KDM4E (0.62) | LMNAADRA2CKDM4EADRA2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264033-A | Synthesis method of oxygen-18 substituted Abediterol precursor | 中国科学技术大学 | 2025-01-07 | — | — | CN | disclosed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-114728168-B | Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| CN-109293692-A | One kind is together with fluoroalkyl boric acid ester compound and its preparation method and application | 中山大学 | 2019-02-01 | — | — | CN | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-7087789-B2 | Methods for nucleophilic fluoromethylation | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | disclosed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | disclosed |
| US-5175302-A | Nucleophilic fluoroalkylation of aldehydes | ETHYL CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| US-4999429-A | Process for the preparation of α,α,β-1-trifluoro-1-olefinic derivatives | ETHYL CORPORATION (US) | 1991-03-12 | — | — | US | disclosed |
| US-4837327-A | Process for nucleophilic fluoroalkylation of aldehydes | ETHYL CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | PHF2, HAO2, GSTM2 | LMNA 4803/4885ADRA2C 1549/4885KDM4E 2596/4885 |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | LMNA 4467/4885ADRA2C 843/4885KDM4E 1350/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | LMNA 4467/4885ADRA2C 843/4885KDM4E 1350/4885 |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885ADRA2C 2636/4885KDM4E 2137/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885ADRA2C 2636/4885KDM4E 2137/4885 |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885ADRA2C 2636/4885KDM4E 2137/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885ADRA2C 2636/4885KDM4E 2137/4885 |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | CTSB, CTSF, CTSZ | LMNA 2544/4885ADRA2C 3889/4885KDM4E 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.